Page last updated: 2024-11-04

vorinostat and Leukemia, Megakaryocytic

vorinostat has been researched along with Leukemia, Megakaryocytic in 2 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Galimberti, S2
Canestraro, M2
Maffei, R2
Marasca, R2
Guerrini, F2
Piaggi, S1
Ciabatti, E1
Petrini, M2
Khan, R1
Buda, G1
Orciuolo, E1
Fazzi, R1

Other Studies

2 other studies available for vorinostat and Leukemia, Megakaryocytic

ArticleYear
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line.
    Leukemia, 2009, Volume: 23, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Electrophoretic

2009
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines.
    Leukemia, 2008, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Screening

2008